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OBJECTIVES We sought to assess the efficacy and safety of thrombolytic therapy in patients with an acute
pulmonary embolism (PE).
BACKGROUND Thrombolytic therapy is approved for the treatment of acute PE; however, the safety and
efficacy of this therapy remain debated.
METHODS A meta-analysis of randomized, controlled trials comparing thrombolytic agents with
intravenous heparin in patients with acute PE was performed. Trials were identified through
a combined search of the MEDLINE, EMBASE, and Current Contents databases. Three
outcome measures were assessed: 1) mortality, 2) recurrence of PE, and 3) major hemorrhage.
RESULTS Nine trials including 461 patients were identified. Compared with intravenous heparin,
thrombolytic therapy had no significant effect on mortality (relative risk [RR] 0.63, 95%
confidence interval [CI] 0.32 to 1.23) or the recurrence of PE (RR 0.59, 95% CI 0.30 to
1.18), but was associated with an increased risk of major hemorrhage (RR 1.76, 95% CI 1.04
to 2.98). These results were homogeneous and largely unaffected by the formulation of
thrombolytic agent, the clinical severity of PE, the extent of vascular obstruction determined
radiologically, or the methodologic quality of the included trials.
CONCLUSIONS Compared with intravenous heparin, thrombolytic therapy does not appear to have thera-
peutic benefit in unselected patients with acute PE, but it is associated with an increased risk
of major hemorrhage. Given the small number of patients included in the randomized trials
thus far, the negative results in terms of the efficacy outcomes should be interpreted with
caution. Definitive evidence of the utility of thrombolytic therapy in this setting requires a
large, randomized, controlled trial. (J Am Coll Cardiol 2002;40:1660–7) © 2002 by the
American College of Cardiology Foundation
Pulmonary embolism (PE) is a common disorder with
significant morbidity and mortality. In the U.S., PE occurs
in approximately 600,000 patients and may be responsible
for over 50,000 deaths annually (1,2). Standard manage-
ment consists of intravenous heparin; this therapy has been
shown to reduce both the recurrence of PE and mortality
(3). However, the three-month mortality of this condition
remains high, ranging from 10% to 17.5% (2), and is even
higher in cases of massive PE (4,5).
Several randomized, controlled trials comparing throm-
bolytic therapy with heparin in patients with an acute PE
have demonstrated more rapid clot resolution in those
treated with thrombolysis (6–13). However, a significant
effect of thrombolytic therapy on important clinical out-
comes, including the recurrence of PE and mortality, has
been difficult to demonstrate, potentially because of the
small sample sizes of the aforementioned trials. Neverthe-
less, because of its rapid effect on pulmonary vascular
resistance, thrombolytic treatment is strongly recommended
in patients with an acute PE associated with shock (2), and
the use of streptokinase, urokinase, and recombinant tissue-
type plasminogen activator (rt-PA) has been approved for
this indication. More recently, based on studies showing
that right ventricular (RV) hypokinesia, as demonstrated on
the echocardiogram, is associated with an adverse clinical
outcome (4,5,9,14), thrombolytic therapy has been advo-
cated in hemodynamically stable patients with RV dysfunc-
tion (15–18). This strategy is supported by a retrospective
study suggesting a beneficial effect of thrombolytic therapy
on survival in this subgroup of patients (19). As 40% to 50%
of patients with PE have echocardiographic evidence of RV
dysfunction (5,9), these recommendations could have sig-
nificant implications. Arguments against this approach in-
clude a lack of definitive evidence for the usefulness of
thrombolytic therapy in this setting (1), the high cost of this
treatment, and its potential for life-threatening side effects,
particularly major hemorrhage (20).
In light of the limitations of the available data describing
the efficacy and safety of thrombolytic therapy in patients
with an acute PE, we performed a meta-analysis of random-
ized, controlled trials comparing thrombolysis with heparin.
By combining the results of individual trials, we hoped to
achieve sufficient statistical power in order to determine
whether a significant treatment effect of thrombolysis truly
exists. In addition, we employed sensitivity analyses to focus
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on patients with severe PE and to determine whether this
subgroup is more likely to achieve a benefit from thrombo-
lytic therapy.
METHODS
This meta-analysis was conducted according to a predeter-
mined protocol following the recommendations of the
QUality Of Reporting Of Meta-analyses (QUOROM)
statement (21). It was not supported by any pharmaceutical
manufacturer, governmental agency, or other grants.
Data search. We reviewed all trials describing thrombo-
lytic therapy in patients with an acute PE. Studies were
identified by electronic searches of the MEDLINE (1967 to
2000), EMBASE (1974 to 2000), and Current Contents
(1967 to 2000) databases. The reference lists of retrieved
articles and published reviews were also searched. In addi-
tion, investigators with expertise in the field and manufac-
turers of thrombolytic agents were contacted for informa-
tion on any missing or unpublished studies.
Inclusion and exclusion criteria. Trials were included if
they met all of the following criteria: 1) planned as a
prospective, randomized, controlled design; 2) published as
an article or abstract; 3) included patients with an acute PE;
4) compared thrombolytic therapy with urokinase, strep-
tokinase, or rt-PA versus heparin; and 5) described at least
one of the following outcome measures: mortality, recur-
rence of PE, or major hemorrhage. Trials were included
regardless of language and blinding. Trials that were retro-
spective, nonrandomized, or quasi-randomized, or that
compared two thrombolytic regimens, were excluded. The
decision regarding inclusion or exclusion of studies was
made before analysis of the data.
Validity assessment and data extraction. Two investiga-
tors (G. T. and D. T.) independently performed the search
for trials and confirmed their eligibility. The same authors
extracted data independently using a structured data collec-
tion instrument, according to the recommendations of
L’Abbe´ et al. (22). Disagreements regarding trial eligibility
or data extraction were resolved by discussion.
Outcome measures. Three outcome measures were as-
sessed to determine the safety and efficacy of thrombolytic
therapy in patients with an acute PE: 1) mortality; 2)
recurrence of PE demonstrated by a perfusion lung scan,
pulmonary angiography, or postmortem examination; and
3) major hemorrhage (defined as intracranial or retroperi-
toneal hemorrhage or other bleeding requiring blood trans-
fusion or surgery). All outcome measures were assessed until
the end of follow-up of each study.
Quality assessment. The methodologic quality of the in-
cluded trials was scored independently by two reviewers
(G. T. and D. T.) using a well-validated scale (23). This
scale consists of three items describing the method of
randomization, blinding, and handling of dropouts and
withdrawals. Scores on the scale range from 0 to 5, with
higher scores indicating better methodologic quality. Any
differences in quality assessment between the authors were
resolved by consensus.
Statistical analysis. All analyses were performed according
to the intention-to-treat principle. For each trial, we calcu-
lated the relative risks (RRs) of the outcomes, defined as the
ratio of the number of patients with the outcome to the total
number of patients in the thrombolytic group, divided by
the same ratio in the heparin group. Thus, a RR below 1.0
indicates a favorable effect of thrombolytic therapy. For each
of the three outcome measures, we calculated a pooled RR
using the Mantel-Haenszel method (fixed-effects model)
(24). If significant heterogeneity (p  0.1), as assessed by
the chi-square test, was detected, the Der Simonian and
Laird method (random-effects model) was used (25). For
statistically significant differences between treatment
groups, the number needed to treat (to prevent a death or
case of recurrent PE) and the number needed to harm (to
cause an episode of major hemorrhage) were calculated as:
1/([control group event rate] [1  RR]). Furthermore, for
each trial, we plotted the treatment effect for mortality
(logarithm of RR) against the inverse of its standard error
(precision). Because the precision increases with the number
of trial participants, the treatment effect estimates from
smaller studies scatter more widely at the bottom of the plot.
Thus, the plot is expected to resemble a symmetrical,
inverted funnel. Significant asymmetry in such plots may be
caused by publication bias (26,27). The degree of asymme-
try in the funnel plot was estimated using regression analysis
(27).
Four sensitivity analyses were performed to more closely
examine the impact of thrombolytic therapy on the three
outcome measures. First, the effect of the type of thrombo-
lytic agent was examined by including only trials adminis-
tering rt-PA. Second, the impact of therapy in patients with
a massive PE was examined. Because only one of the trials
(28) examined this patient subgroup specifically, and none
of the remaining trials reported the results in this subgroup
separately, two post-hoc sensitivity analyses were con-
ducted. First, we assessed the impact of therapy in studies
that included patients in shock. Second, as a surrogate
marker for severe PE, we examined only those trials requir-
ing a specific extent of pulmonary vascular obstruction, as
defined radiologically, for inclusion in the trial. Finally, the
impact of methodologic quality was assessed by excluding
trials with a methodologic quality score equal to or less than
the median value (2) of the included trials.
All results are reported with their 95% confidence interval
Abbreviations and Acronyms
CI  confidence interval
PE  pulmonary embolism
RR  relative risk
RV  right ventricular
rt-PA  recombinant tissue-type plasminogen activator
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(CI). A p value of 0.05 was considered significant. All
statistical analyses were performed using STATA version
6.0 statistical software (Stata Corp., College Station,
Texas).
RESULTS
Selection and characteristics of included trials. A total of
120 references describing thrombolytic therapy in patients
with an acute PE were identified. Nine randomized, con-
trolled trials (6–13,28) including a total of 461 patients met
the inclusion criteria. No abstracts that were not subse-
quently published as full articles were identified. Agreement
between the two reviewers for the eligibility of relevant
articles was 100%.
The characteristics of the included trials, including their
methodologic quality, are summarized in Table 1. The
median methodologic quality score was 2 (range 1 to 3).
Three studies were double-blinded (8,12,13); the remainder
were unblinded (6,7,9–11,28). In six trials, the diagnosis of
PE was made by pulmonary angiography (6,7,10–13),
whereas it was made by either perfusion lung scan or
pulmonary angiography in two trials (8,9) and by perfusion
lung scan only in one trial (28). All trials included patients
with an onset of symptoms consistent with acute PE within
at least 15 days before enrollment. The median time
between the onset of symptoms and the initiation of
treatment was 5 days in all but one study (in which the
mean time was 5.9  1.0 days) (8) and was not reported in
the Prospective Investigation of Pulmonary Embolism Di-
agnosis (PIOPED) study (13). All trials excluded patients
with a contraindication to thrombolytic therapy, and five
trials excluded patients in shock (7–10,13). Shock was
defined as systolic blood pressure 90 mm Hg in all trials,
but only when associated with organ dysfunction in two
trials (11,12). The severity of PE, as judged by the extent of
vascular obstruction on the radiograph (defined variably
according to the study) (Table 1), was an inclusion criterion
in five trials (6,7,10,13,28).
Thrombolytic regimens consisted of rt-PA in four trials
(8–10,13), urokinase in two trials (7,12), and streptokinase
in three trials (6,11,28). In one trial, thrombolytic therapy
was administered through the pulmonary artery (11),
whereas in the remainder of the trials, these agents were
administered intravenously. The dosages of the thrombo-
Table 1. Characteristics of the Included Trials
Study (Year)
[Ref.]
Quality
Score*
Inclusion Criteria;
Method of Diagnosis
Severity
Assessment
Exclusion
Criteria†
Treatment
Regimens
Follow-up
(Days)
UPET (1973) [12] 3 onset 5 days; pulmonary
angiography
no restriction — Heparin, UK 2,000-U/lb
bolus, then 2,000 U/lb
per h IV for 12 h
14
Tibbutt (1974) [11] 3 life-threatening PE;
pulmonary angiography
no restriction — Intrapulmonary heparin,
intrapulmonary SK
600,000-U bolus, then
100,000 U/h for 72 h
3
Ly (1978) [6] 2 onset 5 days; pulmonary
angiography
affecting 1 lobar
artery
age 70 yrs Heparin, SK 250,000-U
bolus, then 100,000 U/h
for 72 h
10
Marini (1988) [7] 1 onset 7 days; pulmonary
angiography
9 unperfused
lung segments
on perfusion
lung scan
age 72 yrs,
shock‡
Heparin, UK 800,000 U/d
IV for 72 h, UK
3,300,000 U IV for 12 h
7
PIOPED (1990) [13] 2 onset 7 days; pulmonary
angiography
occlusion of lobar
artery or 2
segmental
arteries
shock Heparin, rt-PA 40–80 mg
IV over 90 min plus
heparin
7
Levine (1990) [8] 3 onset 15 days;
pulmonary angiography
or perfusion lung scan
no restriction shock Heparin, rt-PA 0.6 mg/kg
IV over 2 min
10
PAIMS 2 (1992) [10] 2 onset 10 days;
pulmonary angiography
Miller index 11 shock Heparin, rt-PA 100 mg IV
over 2 h
7
Goldhaber (1993) [9] 3 onset 14 days;
pulmonary angiography
or perfusion lung scan
no restriction shock Heparin, rt-PA 100 mg IV
over 2 h
14
Jerjes-Sanchez (1995)
[28]
2 onset 14 days; perfusion
lung scan
9 obstructed
segments on
perfusion lung
scan or 9
segments with
RV dysfunction
previous PE Heparin, SK 1,500,000 U
IV over 1 h
3
*Items assessed in the methodologic quality score include method of randomization, double-blinding, handling of dropouts, and withdrawals. †All trials excluded patients with
contraindications to thrombolytic therapy. ‡Shock was defined as systolic blood pressure 90 mm Hg with or without signs of organ dysfunction, depending on the trial.
IV  intravenous; PE  pulmonary embolism; rt-PA  recombinant tissue-type plasminogen activator; RV  right ventricular; SK  streptokinase; UK  urokinase.
1662 Thabut et al. JACC Vol. 40, No. 9, 2002
Thrombolytic Therapy for PE November 6, 2002:1660–7
lytic agents are summarized in Table 1. The dosages of
heparin were adjusted to achieve a target partial thrombo-
plastin time of 1.5 to 2.5 times the upper limit of normal in
all trials.
The median follow-up of the included trials was 7 days
(range 3 to 14 days). Major hemorrhage was defined as
intracranial or retroperitoneal hemorrhage or overt bleeding
requiring blood transfusion in all trials. Although most of
the trials reported the recurrence of PE on the basis of
clinical suspicion, only cases confirmed by a perfusion lung
scan, pulmonary angiography, or postmortem examination
were included in our analysis.
A total of 241 patients were randomized to thrombolysis
and 220 to heparin alone. Their mean age ranged from 47
to 66 years, and the percentage of males ranged from 27% to
100%. Of the 461 patients enrolled in the included trials,
only 24 (5.2%) presented with shock.
Evaluation of the effect of therapy. With the exception of
one study (28), none of the trials showed a significant effect
of thrombolytic therapy on mortality, the recurrence of PE,
or major hemorrhage, as compared with administration of
heparin alone (Table 2). In the lone study showing a
significant reduction in mortality achieved with thrombol-
ysis, a total of eight patients were randomized (four to
thrombolytic therapy and four to heparin); all of the patients
had a massive PE associated with systemic arterial hypoten-
sion. In this trial, all of the patients receiving heparin died,
whereas all of those administered streptokinase recovered.
Meta-analysis. MORTALITY. This outcome measure was
reported in all nine trials including a total of 461 patients
(Fig. 1). There was no statistical heterogeneity among the
trials for this outcome (p  0.77). The mean mortality rates
in the thrombolytic and heparin groups were 4.6% and
7.7%, respectively. The benefit of thrombolytic therapy did
not reach statistical significance (RR 0.63, 95% CI 0.32 to
1.23). The sensitivity analyses (Table 3) did not reveal a
significant difference in mortality between treatments when
the formulation of thrombolytic agent, the clinical severity
of PE, the radiologic severity of pulmonary vascular obstruc-
tion, or methodologic quality were considered.
RECURRENCE OF PE. This outcome measure was reported
in seven trials including a total of 428 patients (Fig. 2).
There was no statistical heterogeneity among the studies for
this outcome (p 0.58). The mean rate of recurrent PE was
4.9% in the thrombolytic group versus 9.3% in the heparin
group. This difference was not statistically significant (RR
0.59, 95% CI 0.30 to 1.18). Sensitivity analyses (Table 3)
did not reveal a significant difference in the recurrence of PE
between treatments when the formulation of thrombolytic
agent, the clinical severity of PE, the radiologic severity of
pulmonary vascular obstruction, or methodologic quality
were considered.
MAJOR HEMORRHAGE. The incidence of major hemorrhage
was reported in all of the trials (Fig. 3). There was no
statistically significant heterogeneity in this analysis (p 
1.0). Overall, thrombolytic therapy was associated with an
increased risk of major hemorrhage, as compared with
heparin (13.7% vs. 7.7%; RR 1.76, 95% CI 1.04 to 2.98).
This difference corresponds to a number needed to harm of
17 (95% CI 7 to 325)—that is, 17 patients need to be
treated with thrombolytic therapy instead of heparin to
Table 2. Individual Results of the Nine Included Randomized, Controlled Trials
Study (Year) [Ref.] Patients Mortality Recurrence of PE* Major Hemorrhage†
UPET (1973) [12] 78/82 7/6 12/10 11/22
Tibbutt (1974) [11] 17/13 1/0 1/0 1/1
Ly (1978) [6] 11/14 2/1 NA 2/4
Marini (1988) [7] 10/20 0/0 0/0 0/0
PIOPED (1990) [13] 4/9 0/1 0/0 0/1
Levine (1990) [8] 25/33 0/1 0/0 0/0
PAIMS 2 (1992) [10] 16/20 1/2 1/1 2/3
Goldhaber (1993) [9] 55/46 2/0 5/0 1/2
Jerjes-Sanchez (1995) [28] 4/4 4/0 NA 0/0
Total 220/241 17 (7.7%)/11 (4.6%) 19 (9.3%)/11 (4.9%) 17 (7.7%)/33 (13.7%)
*Recurrence of PE evaluated in 428 patients (heparin, n 205; thrombolysis, n 223). The diagnosis was made by a perfusion lung scan, pulmonary angiography, or postmortem
examination. †Major hemorrhage is defined as intracranial or retroperitoneal hemorrhage or other bleeding requiring transfusion or surgery. Data are expressed as the number
(%) of patients in the heparin/thrombolysis groups.
NA  not available; PE  pulmonary embolism.
Figure 1. Graphic representation of the relative risk (95% confidence
interval [CI]) of mortality in the thrombolysis versus heparin groups.
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cause an additional episode of major hemorrhage. In the
sensitivity analyses (Table 3), this difference remained sig-
nificant when only the trials randomizing patients in shock
(RR 1.82, 95% CI 1.01 to 3.26) and those with high
methodologic quality (RR 1.90, 95% CI 1.03 to 3.50) were
considered. In trials administering rt-PA and those requir-
ing a particular extent of pulmonary vascular obstruction for
inclusion, the difference in the rates of major hemorrhage
between thrombolytic therapy and heparin were not statis-
tically significant.
FUNNEL-PLOT ANALYSIS. A plot of the logarithm of RR of
mortality versus the precision for each trial is illustrated in
Figure 4. The symmetry of the plot (intercept 0.15; 95% CI
1.06 to 1.37; p  0.50) contradicts the presence of a
publication bias. Similar results were obtained regardless of
the outcome measure assessed (data not shown).
DISCUSSION
Acute PE is a common medical condition. Although the
standard therapy—heparin—is effective, the morbidity and
mortality attributable to acute PE remain high (2,5).
Thrombolytic agents represent an alternative treatment with
convincing biologic plausibility for a benefit. By lysing the
obstructive thrombus, these agents rapidly reverse the RV
dysfunction that is associated with decreased survival in
these patients (4,5,9,14). In addition, thrombolysis serves as
a medical embolectomy, a benefit that could conceivably
lead to a reduction in the rate of recurrent PE. Several
randomized, controlled trials have compared heparin with
thrombolytic agents in patients with an acute PE, but a
beneficial effect of thrombolysis on important clinical out-
comes—namely, survival and the recurrence of PE—has
been difficult to demonstrate. This may relate to the small
sample sizes of the trials thus far reported. To determine
whether a treatment effect of thrombolysis truly exists, we
endeavored to increase the statistical power by pooling the
results of the available trials using meta-analytic techniques.
Our study showed that thrombolytic therapy is not associ-
ated with a significant reduction in mortality or the recur-
rence of PE, as compared with heparin, when administered
to unselected patients with an acute PE. However, throm-
bolytic therapy did lead to a near doubling in the rate of
major hemorrhage, as compared with heparin alone.
Although a significant reduction in mortality and the
recurrence of PE was not demonstrated in patients receiving
thrombolytic agents, there was a trend in favor of this
treatment. The point estimates suggest a reduction of
approximately 40% for both of these outcomes in patients
Figure 2. Graphic representation of the relative risk (95% confidence
interval [CI]) of the recurrence of pulmonary embolism in the thrombolysis
versus heparin groups.
Figure 3. Graphic representation of the relative risk (95% confidence
interval [CI]) of major hemorrhage in the thrombolysis versus heparin
groups.
Table 3. Sensitivity Analyses of Thrombolytic Regimen, Clinical and Radiologic Severity of Pulmonary Embolism, and
Methodologic Quality*
Criterion [Ref.] Mortality
Recurrence of
PE
Major
Hemorrhage
rt-PA as thrombolytic regimen [8–10,13] 1.00 (0.28–3.60) 0.23 (0.04–1.47) 1.54 (0.45–5.26)
Patients in shock included [6,11,12,28] 0.51 (0.23–1.16) 0.76 (0.36–1.61) 1.82 (1.01–3.26)
Severity of vascular obstruction as inclusion criterion [6,7,10,13,28] 0.49 (0.16–1.46) 0.80 (0.05–11.82) 1.40 (0.49–3.99)
Methodologic score 3 [8,9,11,12] 0.73 (0.30–1.75) 0.58 (0.29–1.19) 1.90 (1.03–3.50)
*Items assessed in the methodologic quality score include method of randomization, double-blinding, and handling of dropouts and withdrawals. Results are reported as the
relative risk (95% confidence interval) of the event in the thrombolysis group compared with the heparin group. All analyses used a fixed-effect model.
NA  not available; PE  pulmonary embolism; rt-PA  recombinant tissue-type plasminogen activator.
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treated with thrombolysis versus heparin. Sensitivity analy-
ses showed that these results were robust to the formulation
of thrombolytic agent used and the methodologic quality of
the trials. The failure to detect a significant difference
between treatments has several possible explanations. First
and foremost, a difference may not exist. Alternatively, our
meta-analysis may have been underpowered; despite pool-
ing all of the randomized, controlled trials thus far pub-
lished, only nine trials enrolling a total of 461 patients (241
randomized to thrombolysis) were available. Our funnel-
plot analysis (Fig. 4) suggests that a publication bias—the
failure of small trials to be published due to nonsignificant
treatment effects—does not explain this paucity of data.
The point estimates and CIs for mortality and the recur-
rence of PE suggest that a difference in favor of thrombol-
ysis may become apparent if the sample size were increased.
However, to demonstrate a clinically important difference
between these therapies (e.g., 30% reduction in short-term
mortality) would necessitate the enrollment of approxi-
mately 1,000 patients per treatment arm in a controlled trial
(assuming a 15% three-month mortality rate in the heparin
group and 80% power) (5,29). A potentially similar situation
occurred in the early trials examining the effect of intrave-
nous thrombolytic therapy in patients with an acute myo-
cardial infarction. In this condition, several thousand people
were enrolled in controlled trials before a convincing sur-
vival benefit of thrombolysis was demonstrated (30). Fur-
thermore, this treatment did not become standard clinical
practice until nearly 20,000 patients had been studied (30).
In patients with an acute PE, only a multicenter, prospec-
tive, controlled trial will be able to definitively answer this
question. For various reasons (31), and despite international
calls (32), such a trial has yet to be initiated.
An alternative explanation for the failure to detect a
significant difference in mortality between these treatments
may be that PE, by itself, is not the major cause of death in
these patients. Indeed, in a one-year prospective study of
399 patients (29), most of the deaths were due to underlying
diseases; only 2.5% died as a direct result of their PE.
However, this hypothesis is not supported by the results of
the International COoperative Pulmonary Embolism Reg-
istry (ICOPER) (5). In this prospective study including
2,454 patients, the overall three-month mortality rate was
17.4%; 45% of these deaths were attributed to PE. More-
over, 24% of the deaths were due to respiratory failure or
sudden cardiac death; recurrent PE may have caused a large
proportion of these deaths.
Although the indications for thrombolytic therapy in
patients with a PE have yet to be precisely defined, the
subset of patients with a “massive” PE (i.e., those with RV
dysfunction and hemodynamic instability) has been the
typical target for treatment. To determine whether this
subgroup might be particularly likely to sustain a benefit or
injury from thrombolysis, a sensitivity analysis was planned
in these patients. Unfortunately, only a single trial examined
this population exclusively (28), and the remainder failed to
report these patients’ results separately. Consequently, post-
hoc sensitivity analyses were performed examining only the
trials including patients in shock and those requiring a
minimal extent of pulmonary vascular obstruction, as de-
fined radiologically, for inclusion. Although these defini-
tions are clearly not ideal surrogates for massive PE, neither
analysis revealed a significant benefit of thrombolytic ther-
apy on mortality or the recurrence of PE. However, as only
5% of the trial participants were in shock, any benefit in this
subset may have been masked by a lack of benefit in the
remaining patients. Interestingly, the single trial exclusively
enrolling patients with a massive PE and shock was the only
study to show a significant reduction in mortality with
thrombolysis (28). Nevertheless, this trial included only
eight patients and has been criticized on methodologic
grounds (1,33). Whether thrombolytic therapy has a role in
patients with RV dysfunction but stable hemodynamics is
also unclear from our study. Our results are in accordance
with a retrospective cohort study of 128 patients receiving
thrombolysis or heparin, in which thrombolysis was associ-
ated with an improvement, as demonstrated on perfusion
lung scans, but no difference in the rate of recurrent PE or
mortality (34). However, in a larger study of a similar
population, Konstantinides et al. (19) reported a significant
reduction in mortality and PE recurrence in patients treated
with thrombolysis. The same investigators have recently
reported the results of a prospective, multicenter, placebo-
controlled trial in which 247 patients with a major PE were
randomized to rt-PA plus heparin or placebo plus heparin
(35). In this study, although mortality did not significantly
differ between the two groups, the rt-PA group had a less
“rocky” hospital course, as compared with the placebo
group. Only a large, randomized, controlled trial stratifying
patients according to evidence of RV dysfunction and the
Figure 4. Funnel-plot analysis. Plot of the logarithm of the relative risk of
mortality versus precision of the included trials. The study by Marini et al.
(7) was excluded because the relative risk could not be calculated, as no
deaths occurred in either treatment group. The funnel plot is symmetrical
(intercept 0.15; 95% confidence interval 1.06 to 1.37), contradicting the
presence of a publication bias.
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presence of hemodynamic instability will be able to defi-
nitely resolve these issues.
This meta-analysis demonstrated a significant increase in
the rate of major hemorrhage in patients receiving throm-
bolytic therapy (13.7%) versus heparin (7.7%). This finding
is in accordance with other studies (20,36). According to
this analysis, for every 17 patients treated with thrombolytic
therapy instead of heparin, one additional major hemor-
rhage can be expected. This difference remained significant
regardless of the methodologic quality of the included trials
and the inclusion of patients in shock. Based on the
available data, we could not determine a particular patient
subgroup at risk of this complication; however, advancing
age, larger body mass index, and previous catheterization
have been reported to increase the risk of hemorrhagic
complications (36,37). Interestingly, our sensitivity analysis
including only those trials administering rt-PA failed to
reveal a difference between thrombolytic therapy and hep-
arin in terms of the rate of major hemorrhage, suggesting
that rt-PA may be less likely to cause bleeding, as compared
with streptokinase or urokinase. However, this finding
should be interpreted with caution due to the limited power
of this analysis. Furthermore, a comparison of the relative
risk of major hemorrhage in the trials administering rt-PA
versus that of the other agents revealed a nonsignificant
difference (data not shown). Moreover, direct comparisons
of these agents in randomized, controlled trials have failed
to demonstrate a difference in this outcome (38,39).
Our meta-analysis has several limitations—in particular
and as already alluded to, the small sample size. Neverthe-
less, pooling of all of the currently available data by using
meta-analytic techniques has allowed us to confirm a com-
mon clinical suspicion not yet substantiated in randomized,
controlled trials; namely, that thrombolysis is associated
with an increased risk of bleeding, as compared with
heparin, in patients with an acute PE. Although meta-
analysis does not replace the value of a large, well-designed,
randomized trial, it is nonetheless useful when sample sizes
are individually too small to detect a treatment effect and
label it statistically significant (22). In this setting, there is
some agreement between the overall estimates given by
meta-analyses and subsequently published, large, random-
ized trials (40). Other limitations of meta-analysis are well
known (41,42). Comparative studies yielding conflicting
results are difficult to evaluate because many factors other
than the administered treatments can affect the outcome(s).
As in any meta-analysis, critical attention must be paid to
the quality of the primary trials. In our study, all of the
included trials were prospective, controlled, and random-
ized; all of them incorporated reasonable definitions of the
main outcome measures; and the treatment effects of the
trials were homogeneous. In addition, the methodologic
quality of the trials, as judged by a well-validated quality
score (23), did not affect the results in the sensitivity
analyses. Another limitation of our meta-analysis is the
failure to identify particular patient characteristics that may
predict an enhanced benefit or risk of thrombolytic therapy.
Although an evaluation of treatment effects based on the
presence of RV dysfunction was attempted by use of
sensitivity analyses, an analysis based on individual patient
data would have likely been more enlightening (43).
Conclusions. This meta-analysis revealed an increased risk
of major hemorrhage in patients treated with thrombolytic
therapy versus heparin for acute PE, but it did not detect a
significant difference in the rate of recurrent PE or mortal-
ity. Given the small number of patients enrolled in the
included trials, these negative results should be interpreted
with caution due to a potential lack of statistical power.
Definitive evidence of the usefulness of thrombolytic ther-
apy in this setting requires a large, prospective, randomized,
controlled trial (33).
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